Abstract
Protection of the brain is strengthened by active transport and ABC transporters. P-glycoprotein (P-gp) at the blood-brain barrier (BBB) functions as an active efflux pump by extruding a substrate from the brain, which is important for maintaining loco-regional homeostasis in the brain and protection against toxic compounds. Importantly, dysfunctional BBB P-gp transport is postulated as an important factor contributing to accumulation of aggregated protein in neurodegenerative disorders such as Alzheimers disease (AD) and Parkinsons disease (PD). Furthermore, P-gp is a major factor in mediating resistance to brain entry of numerous exogenous compounds, including toxins that can be involved in PD pathogenesis. This review highlights the role of altered P-gp function in the pathogenesis and progression of neurodegenerative disease. Also the implications of alterations in P-gp function for the treatment of these diseases are discussed.
Keywords: Blood-brain barrier, P-glycoprotein, [11C]-verapamil PET, Parkinson, Alzheimer, Microglia, pesticides, olfactory neurons, progressive supranuclear palsy (PSP), mutation
Current Pharmaceutical Design
Title: Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease
Volume: 17 Issue: 26
Author(s): A.L. Bartels
Affiliation:
Keywords: Blood-brain barrier, P-glycoprotein, [11C]-verapamil PET, Parkinson, Alzheimer, Microglia, pesticides, olfactory neurons, progressive supranuclear palsy (PSP), mutation
Abstract: Protection of the brain is strengthened by active transport and ABC transporters. P-glycoprotein (P-gp) at the blood-brain barrier (BBB) functions as an active efflux pump by extruding a substrate from the brain, which is important for maintaining loco-regional homeostasis in the brain and protection against toxic compounds. Importantly, dysfunctional BBB P-gp transport is postulated as an important factor contributing to accumulation of aggregated protein in neurodegenerative disorders such as Alzheimers disease (AD) and Parkinsons disease (PD). Furthermore, P-gp is a major factor in mediating resistance to brain entry of numerous exogenous compounds, including toxins that can be involved in PD pathogenesis. This review highlights the role of altered P-gp function in the pathogenesis and progression of neurodegenerative disease. Also the implications of alterations in P-gp function for the treatment of these diseases are discussed.
Export Options
About this article
Cite this article as:
Bartels A.L., Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease, Current Pharmaceutical Design 2011; 17 (26) . https://dx.doi.org/10.2174/138161211797440122
DOI https://dx.doi.org/10.2174/138161211797440122 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondrially-Targeted Therapeutic Strategies for Alzheimer’s Disease
Current Alzheimer Research An Up-to-Date Review on Citrus Flavonoids: Chemistry and Benefits in Health and Diseases
Current Pharmaceutical Design Amyloid β-Peptide: The Inside Story
Current Alzheimer Research On the Relationship Between the Light/Dark Cycle, Melatonin and Oxidative Stress
Current Pharmaceutical Design Aggregation Prone Regions and Gatekeeping Residues in Protein Sequences
Current Topics in Medicinal Chemistry Isolation and Characterisation of Acetylcholinesterase Inhibitors from Aquilaria subintegra for the Treatment of Alzheimer’s Disease (AD)
Current Alzheimer Research Microglial Integrity is Maintained by Erythropoietin Through Integration of Akt and Its Substrates of lycogen Synthase Kinase-3β, β-Catenin, and Nuclear Factor-κB
Current Neurovascular Research Withania somnifera Phytochemicals Confer Neuroprotection by Inhibition of the Catalytic Domain of Human Matrix Metalloproteinase-9
Letters in Drug Design & Discovery The Role of β-Amyloid Protein in Synaptic Function: Implications for Alzheimers Disease Therapy
Current Neuropharmacology Editorial (Thematic Issue: MiRNAcles in the Brain: What to Wish and What to Fear)
CNS & Neurological Disorders - Drug Targets Evaluation of Venom as a Promising Tool for Drug Discovery: Focusing on Neurological Disorders
Venoms and Toxins Editorial: Advances in Alzheimer Therapy: Something Old, Something New, Something Borrowed, Something Blue
Current Alzheimer Research The Cannabinoids Switch of Oxidative Stress: A Double-Edged Sword
Mini-Reviews in Organic Chemistry Chaperone Therapy: New Molecular Therapy for Protein Misfolding Diseases with Brain Dysfunction
Current Bioinformatics Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Colon Targeted Rifaximin Nanosuspension for the Treatment of Inflammatory Bowel Disease (IBD)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Current Therapeutic Strategies and Perspectives for Neuroprotection in Parkinson’s Disease
Current Pharmaceutical Design The Glutathione System and its Regulation by Neurohormone Melatonin in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Editorial (Mini Hot-Topic: Determination of the Antioxidant Capacity of Dietary Substances and Extracts from Natural Sources at Molecular, Cellular And Whole Tissue Level: Sensors and Complex Microfluidic Structures)
Current Analytical Chemistry The Development and Progression of Atherosclerosis: Evidence supporting a Role for Endoplasmic Reticulum (ER) Stress Signaling
Cardiovascular & Hematological Disorders-Drug Targets